Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing

被引:25
|
作者
Kuenstner, Axel [1 ,2 ,3 ]
Witte, Hanno M. [4 ,5 ]
Riedl, Joerg [4 ,6 ]
Bernard, Veronica [6 ]
Stoelting, Stephanie [6 ]
Merz, Hartmut [6 ]
Olschewski, Vito [4 ]
Peter, Wolfgang [7 ,8 ,9 ]
Ketzer, Julius [10 ]
Busch, Yannik [7 ]
Trojok, Peter [7 ]
von Bubnoff, Nikolas [3 ,4 ]
Busch, Hauke [1 ,2 ,3 ]
Feller, Alfred C. [6 ]
Gebauer, Niklas [3 ,4 ]
机构
[1] Univ Lubeck, Med Syst Biol Grp, Lubeck, Germany
[2] Univ Lubeck, Inst Cardiogenet, Lubeck, Germany
[3] Univ Hosp Schleswig Holstein, Univ Canc Ctr Schleswig Holstein, Campus Lubeck, Lubeck, Germany
[4] Univ Hosp Schleswig Holstein, Dept Hematol & Oncol, Campus Lubeck, Lubeck, Germany
[5] Fed Armed Forces Hosp Ulm, Dept Hematol & Oncol, Ulm, Germany
[6] Reference Ctr Lymph Node Pathol & Hematopathol, Hamatopathol Lubeck, Lubeck, Germany
[7] Stefan Morsch Fdn, HLA Typing Lab, Birkenfeld, Germany
[8] Univ Cologne, Fac Med, Cologne, Germany
[9] Univ Hosp Cologne, Inst Transfus Med, Cologne, Germany
[10] Univ Hosp Schleswig Holstein, Dept Pediat, Campus Lubeck, Lubeck, Germany
关键词
BURKITT-LYMPHOMA; SURVIVAL; CANCER; EXPRESSION; SIGNATURES; PROGNOSIS; DISTINCT; DLBCL; TOOL;
D O I
10.3324/haematol.2021.279631
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
High-grade B-cell lymphoma accompanied with double/triple-hit MYC and BCL2 and/or BCL6 rearrangements (HGBLDH/TH) poses a cytogenetically-defined provisional entity among aggressive B-cell lymphomas that is traditionally associated with unfavorable prognosis. In order to better understand the mutational and molecular landscape of HGBLDH/TH we here performed whole-exome sequencing and deep panel next-generation sequencing of 47 clinically annotated cases. Oncogenic drivers, mutational signatures and perturbed pathways were compared with data from follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). We find an accumulation of oncogenic mutations in NOTCH, IL6/JAK/STAT and NF.B signaling pathways and delineate the mutational relationship within the continuum between FL/DLBCL, HGBL-DH/TH and BL. Further, we provide evidence of a molecular divergence between BCL2 and BCL6 rearranged HGBL-DH. Beyond a significant congruency with the C3/EZB DLBCL cluster in BCL2 rearranged cases on an exome-wide level, we observe an enrichment of the SBS6 mutation signature in BCL6 rearranged cases. Differential gene set enrichment and subsequent network propagation analysis according to cytogenetically defined subgroups revealed an impairment of TP53 and MYC pathway signaling in BCL2 rearranged cases, whereas BCL6 rearranged cases lacked this enrichment, but instead showed impairment of E2F targets. Intriguingly, HGBL-TH displayed intermediate mutational features considering all three aspects. This study elucidates a recurrent pattern of mutational events driving FL into MYC-driven BCL2-rearranged HGBL, unveiling the mutational pathogenesis of this provisional entity. Through this refinement of the molecular taxonomy for aggressive, germinal center-derived B-cell lymphomas, this calls into question the current World Health Organization classification system, especially regarding the status of MYC/BCL6rearranged HGBL.
引用
收藏
页码:1850 / 1863
页数:14
相关论文
共 50 条
  • [41] Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
    Ella Willenbacher
    Wolfgang Willenbacher
    Roman Weger
    Wolf Dominik
    Claudia Manzl
    Andrea Brunner
    Annals of Hematology, 2020, 99 : 2125 - 2132
  • [42] Transdifferentiation of high-grade B-cell lymphoma with MYC and BCL2 rearrangements into histiocytic sarcoma after CAR T-cell therapy: a case report
    Gauto-Mariotti, Estefania
    Nguyen, Amanda J.
    Waters, Chloe
    Scurti, Gina M.
    Haddad, Sandra
    Velankar, Milind M.
    Dalheim, Annika, V
    Dronzek, Victoria
    Ketterling, Rhett P.
    Nishimura, Michael, I
    Dalland, Joanna C.
    Hossain, Nasheed M.
    JOURNAL OF HEMATOPATHOLOGY, 2022, 15 (04) : 229 - 237
  • [43] Evaluation of the prognostic significance of BCL6 gene expression in canine high-grade B-cell lymphoma
    Sato, Masahiko
    Kanemoto, Hideyuki
    Kagawa, Yumiko
    Kobayashi, Tetsuya
    Goto-Koshino, Yuko
    Mochizuki, Hiroyuki
    Takahashi, Masashi
    Fujino, Yasuhito
    Ohno, Koichi
    Tsujimoto, Hajime
    VETERINARY JOURNAL, 2012, 191 (01) : 108 - 114
  • [44] Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas
    Knezevich, S
    Ludkovski, O
    Salski, C
    Lestou, V
    Chhanabhai, M
    Lam, W
    Klasa, R
    Connors, JM
    Dyer, MJS
    Gascoyne, RD
    Horsman, DE
    LEUKEMIA, 2005, 19 (04) : 659 - 663
  • [45] Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas
    S Knezevich
    O Ludkovski
    C Salski
    V Lestou
    M Chhanabhai
    W Lam
    R Klasa
    J M Connors
    M J S Dyer
    R D Gascoyne
    D E Horsman
    Leukemia, 2005, 19 : 659 - 663
  • [46] BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients
    Akay, Olga Me Item
    Aras, Beyhan Durak
    Isiksoy, Serap
    Toprak, Cigdem
    Mutlu, Fezan Sahin
    Artan, Sevilhan
    Oner, Ulku
    Gulbas, Zafer
    CANCER GENETICS, 2014, 207 (03) : 87 - 93
  • [47] TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations
    Gebauer, Niklas
    Bernard, Veronica
    Gebauer, Wolfgang
    Thorns, Christoph
    Feller, Alfred C.
    Merz, Hartmut
    LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 179 - 185
  • [48] DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
    Akpa, Chidimma Agatha
    Kleo, Karsten
    Lenze, Dido
    Oker, Elisabeth
    Dimitrova, Lora
    Hummel, Michael
    PLOS ONE, 2019, 14 (08):
  • [49] Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
    Wawire, Jonathan
    Sayed, Shahin
    Moloo, Zahir
    Sohani, Aliyah R.
    JOURNAL OF GLOBAL ONCOLOGY, 2019, 5 : 1 - 8
  • [50] Interpreting MYC and BCL2 in diffuse large B-cell lymphoma
    Lai, Catherine
    Grant, Cliona
    Dunleavy, Kieron
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2091 - 2092